Global Markets and Manufacturing Technologies for Protein Drugs

Published - May 2016| Analyst - Shalini Shahani Dewan| Code - BIO021E
Global Markets and Manufacturing Technologies for Protein Drugs
Single User License: $2750 Member Price: FREE

Report Highlights

The global protein drugs market reached nearly $174.7 billion in 2015 and should reach nearly $248.7 billion by 2020 at a compound annual growth rate (CAGR) of 7.3% through 2020.

Report Includes

  • An overview of the markets for each major class of protein in the segments therapeutic monoclonal antibodies, cytokines, peptide hormones, vaccines, and blood products
  • Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020
  • Discussion covering the strength and weaknesses of each type of technology in light of the new technologies, growing competition, and changing customer needs
  • Examinations of current successes, including the size and sales forecast for each class in the next five years
  • Evaluation of challenges such as delivery methods and side effects
  • Consideration of issues regarding add-on products and patent protection
  • Company profiles of major players

Report Scope

The scope of this study covers manufacturing of protein drugs technologies. BCC Research analyzed each market and its applications, regulatory environment, technology, market projections and market shares. Technological issues include the latest trends and developments. This report covers the currently used six techniques in manufacturing of protein therapeutics, which includes fractionation from natural human/animal sources, microbial fermentation, cell culture, chemical synthesis, transgenics and embryonated eggs. The emerging market for enzyme inhibitors includes countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand. The protein drugs that are covered in this report are monoclonal antibodies, cytokines, peptide antibiotics, vaccines, enzymes and blood factors. The market is also analyzed on the basis of the manufacturing process used in making therapeutic protein drugs.

Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead the manufacturing of the protein drug industry. Some of the major players of the market include Eli Lilly & Co., Abbvie Inc., F. Hoffmann-La Roche Ltd., Sanofi S.A., Novo Nordisk AG, Novartis AG, Merck & Co., Merck KGaA and Amgen Inc..

Analyst Credentials

Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Oct-2013| Analyst - Shalini Shahani Dewan| Code - BIO021D

Report Highlights

The global protein therapeutics market reached $138.3 billion in 2012. This market is expected to decline to $136.7 billion in 2013 and then increase to nearly $179.1 billion in 2018, a compound annual growth rate (CAGR) of 5.6% over the five-year period from 2013 to 2018.

Report Includes

  • An overview of the markets for each major class of protein in the segments therapeutic monoclonal antibodies, cytokines, peptide hormones, vaccines, and blood products
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
  • Examinations of current successes, including the size and sales forecast for each class in the next five years
  • Discussion of challenges such as delivery methods and side effects
  • Consideration of issues regarding add-on products and patent protection
  • Comprehensive company profiles of major players.
Published - Oct-2008| Analyst - Amy Brock| Code - BIO021C

Report Highlights

  • The global market for protein drugs is expected to increase from $86.8 billion in 2007 to an estimated $95.2 billion in 2008 and $160.1 billion in 2013, a compound annual growth rate (CAGR) of 10.9%.
  • Peptide hormones generated $26.1 billion in 2007 and an estimated $27.9 billion in 2008. This segment should reach $50.4 billion in 2013, for a CAGR of 12.6%.
  • The antibodies segment was worth $15.0 billion in 2007. This is expected to increase to $18.1 billion in 2008 and $36.9 billion in 2013, for a CAGR of 15.4%.
Published - Jul-2000| Analyst - Rahul Jasuja| Code - BIO021B

Report Highlights

  • Protein drugs for human therapeutic use are a 1,000 metric ton industry-more than one billion grams of bulk proteins that garnered formulation sales, on average, of $27.80 per gram in 1999. This study estimates 1,048,859,344 grams of bulk drug proteins were produced worldwide in 1999. Approximately 1,150,573,386 grams will be produced worldwide in 2004, representing an overall 1.9% average annual (compound) growth rate from 1999 to 2004.
  • Recombinant biological methods provided only 0.1% of the worldwide total bulk drug protein production in 1999, but are projected to provide 0.6% of the total production in 2004.

CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report